Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks von Craig, Timothy J., MD, Levy, Robyn J., MD, Wasserman, Richard L., PhD, MD, Bewtra, Againdra K., MD, Hurewitz, David, MD, Obtułowicz, Krystyna, MD, Reshef, Avner, MD, Ritchie, Bruce, MD, Moldovan, Dumitru, MD, Shirov, Todor, MD, Grivcheva-Panovska, Vesna, MD, Kiessling, Peter C., PhD, Keinecke, Heinz-Otto, MS, Bernstein, Jonathan A., MD

Volltext

Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis von Bril, Vera, Lampe, Johannes, Cooper, Nichola, Kiessling, Peter, Gardulf, Ann

Volltext

Metabolic engineering in strawberry fruit uncovers a dormant biosynthetic pathway von Hoffmann, Thomas, Kurtzer, Robert, Skowranek, Kilian, Kießling, Peter, Fridman, Eyal, Pichersky, Eran, Schwab, Wilfried

Volltext

Prospective Study of Rapid Relief Provided by C1 Esterase Inhibitor in Emergency Treatment of Acute Laryngeal Attacks in Hereditary Angioedema von Craig, Timothy J, Wasserman, Richard L, Levy, Robyn J, Bewtra, Againdra K, Schneider, Lynda, Packer, Flint, Yang, William H, Keinecke, Heinz-Otto, Kiessling, Peter C

Volltext

How the green alga Chlamydomonas reinhardtii keeps time von Schulze, Thomas, Prager, Katja, Dathe, Hannes, Kelm, Juliane, Kießling, Peter, Mittag, Maria

Volltext

Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks von Bernstein, Jonathan A., MD, Ritchie, Bruce, MD, Levy, Robyn J., MD, Wasserman, Richard L., MD, PhD, Bewtra, Againdra K., MD, Hurewitz, David S., MD, Obtulowicz, Krystyna, MD, Reshef, Avner, MD, Moldovan, Dumitru, MD, Shirov, Todor, MD, Grivcheva-Panovska, Vesna, MD, Kiessling, Peter C., PhD, Schindel, Fritz, MS, Craig, Timothy J., DO

Volltext

Prospective study of C1 esterase inhibitor in the treatment of successive acute abdominal and facial hereditary angioedema attacks von Wasserman, Richard L., MD, PhD, Levy, Robyn J., MD, Bewtra, Againdra K., MD, Hurewitz, David, MD, Craig, Timothy J., MD, Kiessling, Peter C., PhD, Keinecke, Heinz-Otto, MS, Bernstein, Jonathan A., MD

Volltext

Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations von Peter, Hans-Hartmut, Ochs, Hans D, Cunningham-Rundles, Charlotte, Vinh, Donald C, Kiessling, Peter, Greve, Bernhard, Jolles, Stephen

Volltext

Phase I Comparability of Recombinant Human Albumin and Human Serum Albumin von Bosse, Dietrich, Praus, Michaela, Kiessling, Peter, Nyman, Lars, Andresen, Corina, Waters, Joanne, Schindel, Fritz

Volltext

Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies von Berger, Melvin, Rojavin, Mikhail, Kiessling, Peter, Zenker, Othmar

Volltext

Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial von Bril, Vera, Benatar, Michael, Andersen, Henning, Vissing, John, Brock, Melissa, Greve, Bernhard, Kiessling, Peter, Woltering, Franz, Griffin, Laura, Van den Bergh, Peter

Volltext

Proof-of-Concept and Safety of the Anti-FcRn Antibody Rozanolixizumab in Patients with Moderate-to-Severe Generalized Myasthenia Gravis (GMG): A Phase 2a Study (S43.001) von Bril, Vera, Benatar, Michael, Brock, Melissa, Greve, Bernhard, Kiessling, Peter, Woltering, Franz, Van den Bergh, Peter

Volltext

Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia von Robak, Tadeusz, Kaźmierczak, Maciej, Jarque, Isidro, Musteata, Vasile, Treliński, Jacek, Cooper, Nichola, Kiessling, Peter, Massow, Ute, Woltering, Franz, Snipes, Rose, Ke, Juan, Langdon, Grant, Bussel, James B., Jolles, Stephen

Volltext

Author Response von Wasserman, Richard L, Levy, Robyn J, Bewtra, Againdra K, Hurewitz, David, Craig, Timothy J, Kiessling, Peter C, Keinecke, Heinz-Otto, Bernstein, Jonathan A

Volltext

Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases von Ochs, Hans D, Gupta, Sudhir, Kiessling, Peter, Nicolay, Uwe, Berger, Melvin

Volltext

Phase II, Multiple-Dose Study of Anti-FcRn Antibody, Rozanolixizumab (UCB7665), in Patients with Primary Immune Thrombocytopenia: Interim Analysis von Robak, Tadeusz, Jarque, Isidro, Musteata, Vasile, Kiessling, Peter, Massow, Ute, Higginson, James, Snipes, Rose, Jolles, Stephen

Volltext

Move More, Sit Less? Analysis of an Employer Activity Tracker Workplace Wellness Program: 1751 Board #2 June 1 1 00 PM - 3 00 PM von Kiessling, Peter B., Kennedy-Armbruster, Carol, Deinhart, Mariah, Kerby, Mary, Ryder, Rachel, Zukerman, Katherine, Schaefer, Samantha

Volltext

Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia von Robak, Tadeusz, Kaźmierczak, Maciej, Jarque, Isidro, Musteata, Vasile, Trelinski, Jacek, Cooper, Nichola, Kiessling, Peter, Massow, Ute, Woltering, Franz, Snipes, Rose, Ke, Juan, Langdon, Grant, Haier, Birgit, Bussel, James B., Jolles, Stephen

Volltext

Antineonatal Fc Receptor Antibody Treatment Ameliorates MOG-IgG–Associated Experimental Autoimmune Encephalomyelitis von Remlinger, Jana, Madarasz, Adrian, Guse, Kirsten, Hoepner, Robert, Bagnoud, Maud, Meli, Ivo, Feil, Moritz, Abegg, Mathias, Linington, Christopher, Shock, Anthony, Boroojerdi, Babak, Kiessling, Peter, Smith, Bryan, Enzmann, Volker, Chan, Andrew, Salmen, Anke

Volltext

Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home von Gardulf, Ann, Nicolay, Uwe, Asensio, Oscar, Bernatowska, Ewa, Böck, Andreas, Costa-Carvalho, Beatriz T., Granert, Carl, Haag, Stefan, Hernández, Dolores, Kiessling, Peter, Kus, Jan, Matamoros, Nuria, Niehues, Tim, Schmidt, Sigune, Schulze, Ilka, Borte, Michael

Volltext